ATE521640T1 - Anti-tsg101-antikörper und ihre verwendungen bei der behandlung von virusinfektionen - Google Patents

Anti-tsg101-antikörper und ihre verwendungen bei der behandlung von virusinfektionen

Info

Publication number
ATE521640T1
ATE521640T1 AT03776217T AT03776217T ATE521640T1 AT E521640 T1 ATE521640 T1 AT E521640T1 AT 03776217 T AT03776217 T AT 03776217T AT 03776217 T AT03776217 T AT 03776217T AT E521640 T1 ATE521640 T1 AT E521640T1
Authority
AT
Austria
Prior art keywords
treatment
antibodies
tsg101
virus infections
provides methods
Prior art date
Application number
AT03776217T
Other languages
English (en)
Inventor
Limin Li
Original Assignee
Functional Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Functional Genetics Inc filed Critical Functional Genetics Inc
Application granted granted Critical
Publication of ATE521640T1 publication Critical patent/ATE521640T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/116—Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT03776217T 2002-10-01 2003-10-01 Anti-tsg101-antikörper und ihre verwendungen bei der behandlung von virusinfektionen ATE521640T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41529902P 2002-10-01 2002-10-01
PCT/US2003/031233 WO2004031209A2 (en) 2002-10-01 2003-10-01 Anti-tsg101 antibodies and their uses for treatment of viral infections

Publications (1)

Publication Number Publication Date
ATE521640T1 true ATE521640T1 (de) 2011-09-15

Family

ID=32069836

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03776217T ATE521640T1 (de) 2002-10-01 2003-10-01 Anti-tsg101-antikörper und ihre verwendungen bei der behandlung von virusinfektionen

Country Status (8)

Country Link
US (2) US7427468B2 (de)
EP (1) EP1546415B1 (de)
JP (1) JP4931347B2 (de)
AT (1) ATE521640T1 (de)
AU (1) AU2003283990B2 (de)
CA (1) CA2500596C (de)
IL (1) IL167774A (de)
WO (1) WO2004031209A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE521640T1 (de) 2002-10-01 2011-09-15 Functional Genetics Inc Anti-tsg101-antikörper und ihre verwendungen bei der behandlung von virusinfektionen
US8476009B2 (en) * 2002-10-01 2013-07-02 Functional Genetics, Inc. Methods for detecting enveloped virus infections by measuring cell surface TSG101
AU2007323900B2 (en) * 2006-11-13 2013-05-09 Eli Lilly And Company Therapeutic targeting of escort proteins
EP2514439A1 (de) * 2006-11-15 2012-10-24 Functional Genetics, Inc. Anti-TSG101-Antikörper und deren Verwendung bei der Behandlung von Virusinfektionen
RU2010120686A (ru) * 2007-10-24 2011-11-27 Фанкшенл Дженетикс,Инк. (Us) Способы ингибирования вирусной инфекции
WO2011091395A1 (en) * 2010-01-25 2011-07-28 Functional Genetics, Inc. Antibodies for diagnosis and therapeutic treatment of prostate cancer
WO2018085208A1 (en) 2016-11-02 2018-05-11 The Research Foundation For The State University Of New York Methods of inhibiting viruses using compositions targeting tsg101-ubiquitin interaction

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
EP0604580A1 (de) 1991-09-19 1994-07-06 Genentech, Inc. Expression in E.Coli von Antikörperfragmenten mit mindestens einem cystein in freier -SH Form. Anwendung in der Herstellung bifunktioneller Antikörper.
JP4021484B2 (ja) * 1995-11-16 2007-12-12 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ 腫瘍の表現型を特徴付けする方法
WO1998016101A1 (en) * 1996-10-15 1998-04-23 Bio-Tech Imaging, Inc. Reagent system and kit for detecting hiv infected cells
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
US7427488B2 (en) * 2000-12-22 2008-09-23 The University Of North Carolina At Chapel Hill Purified and isolated platelet calcium channel nucleic acids and polypeptides and therapeutic and screening methods using same
US20020177207A1 (en) * 2001-03-14 2002-11-28 Myriad Genetics, Incorporated Tsg101-interacting proteins and use thereof
AU2002257067A1 (en) * 2001-03-14 2002-09-24 Myriad Genetics, Inc Tsg101-gag interaction and use thereof
AU2002324753A1 (en) * 2001-08-20 2003-07-09 Myriad Genetics, Inc Composition and method for treating viral infection
AU2003301759A1 (en) * 2002-05-15 2004-05-25 University Of Utah Research Foundation Human vps4a and vps4b functions in viral budding
ATE521640T1 (de) 2002-10-01 2011-09-15 Functional Genetics Inc Anti-tsg101-antikörper und ihre verwendungen bei der behandlung von virusinfektionen

Also Published As

Publication number Publication date
CA2500596C (en) 2013-11-19
EP1546415A2 (de) 2005-06-29
US7427468B2 (en) 2008-09-23
US8182985B2 (en) 2012-05-22
AU2003283990A1 (en) 2004-04-23
JP4931347B2 (ja) 2012-05-16
CA2500596A1 (en) 2004-04-15
IL167774A (en) 2011-12-29
WO2004031209A2 (en) 2004-04-15
EP1546415B1 (de) 2011-08-24
EP1546415A4 (de) 2006-01-11
US20040223972A1 (en) 2004-11-11
WO2004031209A3 (en) 2005-01-13
AU2003283990B2 (en) 2009-04-30
US20090087438A1 (en) 2009-04-02
JP2006514921A (ja) 2006-05-18

Similar Documents

Publication Publication Date Title
EA200700243A1 (ru) Способы лечения гепатита с
DE50214416D1 (de) Vermehrung von viren in zellkultur
NO20051969L (no) Nukleosidderivater for behandling av hepatitt C virusinfeksjon.
CY1122841T1 (el) Πολυαλκυλενικες πολυμερικες ενωσεις και χρησεις αυτων
EA200501689A1 (ru) Соединения в качестве ингибиторов вируса гепатита c
ATE412667T1 (de) Langwirkende fusionspeptidinhibitoren gegen hiv- infektion
EA200401436A1 (ru) Ингибиторы протеазы вич для лечения инфекции вич и фармацевтическая композиция
CY1110665T1 (el) Αναστολεις hiv ιντεγκρασης
ATE474827T1 (de) Hcv-replikationshemmer
DK1802650T3 (da) 3-ether- og 3-thioether-substituerede cyklosporinderivater til behandling og forebyggelse af hepatitis C-infektion
ATE310089T1 (de) Von dem syndrom der weissen flecken virus abgeleitete proteine und deren verwendungen
MX2009005026A (es) Anticuerpos anti-tsg101 y sus usos para tratamiento de infecciones virales.
EA200500533A1 (ru) Пептидные производные - ингибиторы слияния при вич-инфекции
EP1546415A4 (de) Anti-tsg101-antikörper und ihre verwendungen bei der behandlung von virusinfektionen
DE60032915D1 (de) Gallium komplexe von 3-hydroxy-4-pyronen zur behandlung von durch intrazelluläre prokaryoten, dns- und retro-viren verursachten infektionen
ATE474587T1 (de) Inhibitoren des hepatitis-c-virus
ATE370160T1 (de) Peptide mit affinität zu gp120, und ihre verwendungen
ATE532509T1 (de) Mittel zur hemmung des eintritts des hiv-virus
ATE401573T1 (de) Tsg101 als inhibitor der hiv-produktion
DE60232785D1 (de) Tsg101-gag-wechselwirkung und ihre verwendung
WO2007002172A3 (en) Hiv-1 protease inhibitors
DE602005016552D1 (de) Parapocken-viren in kombination mit anderen antiviralen mitteln zur behandlung von hiv/aids
UA41338C2 (uk) Спосіб інгібування ретровірусної інфекції, яка викликана вірусом імунодефіциту людини (віл), спосіб інгібування вірусу імунодефіциту людини (віл)
CY1105629T1 (el) Πολυπεπτιδιο που επαγει αντισωματα εξουδετερωσης του ηιv
EA200500287A1 (ru) Производные 4-(3, 5-дицианофенокси)пиразола для применения в качестве модуляторов обратной транскриптазы в лечении, в числе прочего, вич-инфекции

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties